Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 7th International Workshop on Acute Leukemias (iwAL) took place on 19-21 September, 2025, in Washington DC, and brought together the world’s leading clinicians and researchers in acute leukemias to discuss the latest updates in the field.
Enduring Content from iwAL 2025 has been supported by: Astellas Pharma (Platinum Supporter), Johnson & Johnson (Platinum Supporter), AbbVie (Gold Supporter), Daiichi Sankyo (Gold Supporter), Genentech (Gold Supporter), Sumitomo Pharma (Gold Supporter), Cullinan Therapeutics (Silver Supporter), Kura Oncology (Silver Supporter), Stemline Therapeutics (Silver Supporter), Syndax (Silver Supporter) and Aptose Biosciences (Bronze Supporter). Supporters of the workshop have no influence over the production of content.
iwAL 2025
The 7th International Workshop on Acute Leukemias
19–21 September 2025 | Washington DC, USA
The 7th International Workshop on Acute Leukemias (iwAL) took place on 19-21 September, 2025, in Washington DC, and brought together the world’s leading clinicians and researchers in acute leukemias to discuss the latest updates in the field.
Enduring Content from iwAL 2025 has been supported by: Astellas Pharma (Platinum Supporter), Johnson & Johnson (Platinum Supporter), AbbVie (Gold Supporter), Daiichi Sankyo (Gold Supporter), Genentech (Gold Supporter), Sumitomo Pharma (Gold Supporter), Cullinan Therapeutics (Silver Supporter), Kura Oncology (Silver Supporter), Stemline Therapeutics (Silver Supporter), Syndax (Silver Supporter) and Aptose Biosciences (Bronze Supporter). Supporters of the workshop have no influence over the production of content.
Roundtable discussions
View all
Expert interviews
View all
MRD group session
Translational and lab developments
New science
Transplant
Established Updates
Immunotherapies in AML
Targeting FLT3-mutant AML
International trials group
MRD
CH, BPDCN & CMML
Menin inhibition
TP53-mutated AML
Novel targets & treatments Part I
Novel targets & treatments Part II
Keynote talks
iwAL MRD working group session
Part 1: Prognostic implications
Flow cytometry
Sanam Loghavi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
NPM1
Jad Othman Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
FLT3
Christopher Hourigan Virginia Tech FBRI Cancer Research Center, Washington D.C, United States
Should we intervene at MRD persistence or recurrence?
Farhad Ravandi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Part 3: MRD-directed therapies
MRD intervention trials – learnings from INTERCEPT
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
Using FLT3 and NPM1 MRD to guide treatment
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Part 4: FDA perspective
FDA clinical perspective
Cara Rabik FDA, Silver Sping, MD, United States
Translational and lab developments and applications in AML
Clonal evolution of therapy-related myeloid neoplasms
Koichi Takahashi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
RAS pathway activation drives resistance to gilteritinib and venetoclax
Catherine Smith University of California, San Francisco, San Francisco, CA, United States
New science implications for AML
Stem cells in human AML
Ravi Majeti Stanford University School of Medicine, Stanford, CA, United States
Transcriptomic and geographical mapping of extramedullary AML
Iannis Aifantis University of New York, New York City, NY, United States
The aging of the blood system and diagnosis of leukemia from peripheral blood
Liran Shlush Weizmann Institute of Science, Rehovot, Israel
Transplantation in AML
Strategies to optimize transplant outcomes
Charles Craddock University of Birmingham, Birmingham, United Kingdom
Debate: is pre-transplant intervention warranted in patients with MRD+ AML in CR1? - Yes
Maximilian Stahl Yale Cancer Center, New Haven, CT, United States
Debate: is pre-transplant intervention warranted in patients with MRD+ AML in CR1? - No
Roland Walter Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Updates on established therapies in AML
Optimal approach to the treatment of secondary/therapy-related AML
Tara Lin The University of Kansas Cancer Center, Kansas City, KS, United States
Venetoclax de-escalation
Stéphane de Botton Gustave Roussy, Paris, France
Immunotherapies in AML
NK cell-based therapies in AML
Jeffrey Miller University of Minnesota, Minneapolis, MN, United States
TCEs & CAR-T in AML: let’s try that again
Marion Subklewe LMU Hospital Munich, Munich, Germany
Loss of the Y chromosome defines an immunologically distinct AML subtype with favorable response to cytotoxic chemotherapy
Ann-Kathrin Eisfeld The Ohio State University, Columbus, OH, United States
Targeting FLT3-mutant AML
Designing and applying a FLT3-like signature in AML
Adrián Mosquera Orgueira University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
Frontline approaches for FLT3-mutant AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Current approaches and challenges for relapsed FLT3-mutant AML
Jessica Altman Northwestern University, Chicago, IL, United States
International trials group
UK trials
Charles Craddock University of Birmingham, Birmingham, United Kingdom
US trials
Harry Erba Duke Cancer Institute, Durham, NC, United States
MRD
Value and utility of MRD in the management of adults with newly-diagnosed AML
Debate: MRD is a universally accepted assay/standard of care for the management of fit adults with newly-diagnosed AML - For
Sanam Loghavi, The University of Texas MD Anderson Cancer Center, Houston, TX, United States & Roland Walters, Fred Hutchinson Cancer Research Center, Seattle, WA
Debate: MRD is a universally accepted assay/standard of care for the management of fit adults with newly-diagnosed AML - Against
Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA & Justin Watts, University of Miami, Miami, FL, USA
New frontiers in MRD for AML: regulatory perspective and clinical practice
Cell-free DNA determinants of AML MRD
Tian Yi Zhang Stanford Cancer Institute , Stanford , CA, United States
Clonal hematopoiesis, BPDCN & CMML
CHIP and CCUS: updates and ongoing trials
Uma Borate Ohio State University, Columbus, OH, United States
PI3 kinase gamma: a novel target across AML, BPDCN, and CMML
Andrew Lane Dana-Farber Cancer Institute, Boston, MA, United States
Menin inhibition in AML
Single-agent menin inhibitors – efficacy, biomarkers and resistance
Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Menin inhibitor combinations
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
Venetoclax or menin inhibitors for NPM1-mutated AML
Eytan Stein Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Mechanisms of resistance to menin inhibitors
Amir Fathi Massachusetts General Hospital Cancer Center, Boston, MA, United States
TP53-mutated AML
Future strategies for TP53-mutated AML: how do we improve outcomes?
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Treating TP53-mutated AML after failure of frontline ven/HMA
Gabriel Mannis Stanford University School of Medicine, Stanford, CA, United States
Novel targets, combinations and treatments in AML part I
IC+VEN in newly diagnosed fit AML – who are the optimal patients for this approach?
Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Optimal use of OGM and RNA translocation panel in frontline AML
Sanam Loghavi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Novel targets, combinations and treatments in AML part II
Promising combination options with AZA/VEN for R/R AML
Thomas Cluzeau Central University Hospital of Nice, France
Emerging combination strategies in AML
Himachandana Atluri The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Keynote talks
Never waste a crisis: time to reimagine clinical trial delivery to the benefit of patients, academia and pharma
Charles Craddock University of Birmingham, Birmingham, United Kingdom
